• To clarify the independent cell-cycle mechanisms through which the master regulators FOXM1 and CENPF contribute to acquisition of the lethal metastatic phenotype and therapeutic failure.
  • To investigate how the aberrant expression of chromatin modifiers in castration-resistant metastatic prostate cancer affects the AR cistrome and contributes to enzalutamide resistance.
  • To describe the spectrum of chromatin accessibility in advanced castration-resistant prostate cancer to complement the existing transcriptomic and genomic datasets.

Orthoxenografts of testicular germ cell tumors demonstrate genomic changes associated with cisplatin resistance and identify PDMP as a re-sensitizing agent.

Piulats JM, Vidal A, García-Rodríguez FJ, Muñoz C, Nadal M, Moutinho C, Martínez-Iniesta M, Mora J, Figueras A, Guinó E, Padullés L, Aytés À, Molleví DG, Puertas S, Martínez-Fernández C, Castillo W, Juliachs M, Moreno V, Muñoz P, Stefanovic M, Pujana MA, Condom E, Esteller M, Germà JR, Capella G, Farré L, Morales A, Viñals F, García-Del-Muro X, Cerón J, Villanueva A

CLINICAL CANCER RESEARCH (ISSN/ISBN: 10780432)

2018

See full list

Mecanismos epigenéticos de resistencia a la castración en cancer de próstata: oportunidades terapéuticas en combinación con antagonistas del receptor de andrógenos.

Aytes Meneses, Alvaro (Investigador principal (IP))

Ref.: PI16/01070

Entitat finançadora:
  • FIS-INSTITUTO DE SALUD CARLOS III

2017-01-01 - 2019-12-31

PIE16/00049

Aytes Meneses, Alvaro (Investigador principal (IP))

Ref.: PIE16/00049

Entitat finançadora:
  • FIS-INSTITUTO DE SALUD CARLOS III

2017-01-01 - 2019-12-31

Mecanismos epigenéticos de resistencia a la castración en cancer de próstata: oportunidades terapéuticas en combinación con antagonistas del receptor de andrógenos

Aytes Meneses, Alvaro (Investigador principal (IP))

Ref.: IN[16]_BBM_TRA_0364AyudasFBBVAInvestigadoresyCreadoresCulturales

Entitat finançadora:
  • FUNDACIÓN BBVA

2016-10-01 - 2018-03-31

Identification of molecular drivers of metastatic prostate cancer: the role of FOXM1 and CENPF in the deregulation of the epigenetic control of gene expression. IP: Alvaro Aytes Agencia Financiadora: ISCIII

Aytes Meneses, Alvaro (Coordinador/a científico/a)

Ref.: CP15/00090

Entitat finançadora:
  • MIGUEL SERVET TIPO TIPO I
  • INSTITUTO DE SALUD CARLOS III

2016-01-29 - 2019-01-28

Investigating causal mechanisms and novel therapeutic targets in CRPC after AR blockade failure.

Aytes Meneses, Alvaro (Investigador principal (IP)); Condom Munda, Enric (Participante)

Entitat finançadora:
  • EAU RESEARCH FOUNDATION

2016-01-29 - 2019-01-28

CONTRATOS MIGUEL SERVET TIPO I (CONTRATO)

Aytes Meneses, Alvaro (Investigador principal (IP))

Ref.: MS15/00090

Entitat finançadora:
  • FIS-INSTITUTO DE SALUD CARLOS III

2016-01-29 - 2021-01-28

Investigating causal mechanisms and novel therapeutic targets in CRPC after AR blockade failure

Vidal Bel, August (Participante); Aytes Meneses, Alvaro (Coordinador del proyecto total, red o consorcio)

Ref.: EAURF/407003/XH

Entitat finançadora:
  • EUROPEAN ASSOCIATION OF UROLOGY RESEARCH FOUNDATION - CAREER TRACK

2016-01-01 - 2018-12-31

Identification of molecular drivers of metastatic prostate cancer: the role of FOXM1 and CENPF in the deregulation of the epigenetic control of gene expression.

Aytes Meneses, Alvaro (Investigador principal (IP))

Ref.: CP15/00090MiguelServetI(proyecto)

Entitat finançadora:
  • FIS-INSTITUTO DE SALUD CARLOS III

2016-01-01 - 2018-12-31

A systems approach to identify molecular drivers and new therapeutic targets in metastatic prostate cancer

Aytes Meneses, Alvaro (Coordinador/a científico/a)

Entitat finançadora:
  • PROGRAMA ESTATAL DE I+D+I ORIENTADA A LOS RETOS DE LA SOCIEDAD

2015-09-01 - 2018-08-31

Elucidation of cancer pathways and druggable targets using mouse models

Aytes Meneses, Alvaro (Investigador/a)

Entitat finançadora:
  • NCI/NIH MOUSE MODELS OF HUMAN CANCER CONSORTIUM

2011-01-01 - 2015-01-01

See full list

Proyectos financiados por el Instituto de Salud Carlos III (ISCIII) y cofinanciados por el Fondo Europeo de Desarrollo Regional (FEDER):

 

Identification of molecular drivers of metastatic prostate cancer: the role of FOXM1 and CENPF in the deregulation of the epigenetic control of gene expression

CP15/00090. 01/2016-12/2018. 121.500 €. IP: Álvaro Aytés Meneses.

MS15/00090. 01/2016-01/2021. 202.500 €. IP: Álvaro Aytés Meneses.

Estudio del papel de la activación de FOXM1 y CENPF en la malignización del cáncer de próstata y si esta está mediada por mecanismos epigenéticos.